Relationship of symptom duration and fecal bacteriotherapy in<i>Clostridium difficile</i>infection-pooled data analysis and a systematic review

Sofi, Aijaz; Silverman, Ann L.; Khuder, Sadik A.; Garborg, Kjetil; Westerink, Julie M A; Nawras, Ali

doi:10.3109/00365521.2012.743585

Cited by 28 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These bacteria are influenced by one another as well as by the host. This point has been well documented in several model systems, which demonstrate that bacteria use small molecules such as bile acids to communicate and survive (Sofi et al, 2013). Bile acids in the cecum are deconjugated by microbial-derived bile salt hydrolases into primary bile acids such as cholate (Ridlon et al, 2006), which can stimulate the germination of C. difficile spores (Francis et al, 2013).…”

mentioning

confidence: 95%

“…Consequently, some individuals become refractory to antibiotics and have recurrent CDI. On a brighter note, the use of fecal microbiota transplants (FMTs) as a therapy has been very effective in the treatment of relapsing CDI (Sofi et al, 2013). Yet a major gap exists in our understanding of the interaction between the host-microbe relationship and the microbial factors that confer resistance and susceptibility to CDI.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Dysfunctional Families: Clostridium scindens and Secondary Bile Acids Inhibit the Growth of Clostridium difficile

2015

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 95%

mentioning

confidence: 99%

Dysfunctional Families: Clostridium scindens and Secondary Bile Acids Inhibit the Growth of Clostridium difficile

2015

View full text Add to dashboard Cite

show abstract

“…It is because these individuals and the recipients have similar intestinal microenvironment, which may produce a satisfactory effect of transplantation. While a meta‐analysis showed no significant differences in the effectiveness between related and unrelated donors ( P = 0.46), It has been suggested that male donors are preferred to female donors because feces of the latter might carry high‐risk factors of IBS . Another research indicated gender differences between donors and recipients had little effect on disease remission, but there owned insufficient evidence .…”

Section: The Mechanism and Clinical Use Of Fmtmentioning

confidence: 98%

Update on intestinal microbiota in Crohn's disease 2017: Mechanisms, clinical application, adverse reactions, and outlook

Shen

Zhu

Quan

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

The pathogenesis of Crohn's disease (CD) is complex, and it is thought to be associated with the environment, immune, hereditary, microbe, and other factors. If the balance between the host and the intestinal microbes in CD patients was broken, immuneinflammatory response of susceptible individuals might be triggered. Probiotics could improve the intestinal microbial flora balance and treat human effectively. There are several new mechanisms that might explain the role of probiotics. Fecal microbiota transplantation (FMT) is becoming more and more attractive in treating a large amount of digestive system diseases that are related to the dysbiosis of intestinal microbiota. FMT has been widely used in recurrent Clostridium difficile infection. More and more attention has been paid on the clinical application of FMT in CD, while the exact mechanism is still a mystery. So in this review, we explore the mechanism, clinical application, and adverse reactions of intestinal microbiota in CD so that we can use the tool to cure more diseases. Enteric microbiota leads to new therapeutic strategies for CD.

show abstract

“…FMT is one therapy that has risen in prominence since the early 2010s, due primarily to its startlingly high efficacy (over 90% success rate reported in some studies (125, 126)). FMT, however, is not a new idea.…”

Section: Fecal Microbiota Transplantation (Fmt)mentioning

confidence: 99%

Control of Clostridium difficile Infection by Defined Microbial Communities

Collins

Auchtung

2017

Microbiol Spectr

View full text Add to dashboard Cite

Summary Each year in the United States, billions of dollars are spent combating almost half a million Clostridium difficile infections (CDI) and trying to reduce the ~29,000 patient deaths where C. difficile has an attributed role (1). In Europe, disease prevalence varies by country and level of surveillance, though yearly costs are estimated at €3 billion (2). One factor contributing to the significant healthcare burden of C. difficile is the relatively high frequency of recurrent C. difficile infections(3). Recurrent C. difficile infection (rCDI), i.e., a second episode of symptomatic CDI occurring within eight weeks of successful initial CDI treatment, occurs in ~25% of patients with 35-65% of these patients experiencing multiple episodes of recurrent disease(4, 5). Using microbial communities to treat rCDI, either as whole fecal transplants or as defined consortia of bacterial isolates have shown great success (in the case of fecal transplants) or potential promise (in the case of defined consortia of isolates). This review will briefly summarize the epidemiology and physiology of C. difficile infection, describe our current understanding of how fecal microbiota transplants treat recurrent CDI, and outline potential ways through which that knowledge can be used to rationally-design and test alternative microbe-based therapeutics.

show abstract

Relationship of symptom duration and fecal bacteriotherapy inClostridium difficileinfection-pooled data analysis and a systematic review

Abstract: FMT is a safe and effective treatment option for CDI. Shorter duration of symptoms (< 60 days) before administering FMT is associated with treatment failure.

Cited by 28 publications

References 30 publications

Dysfunctional Families: Clostridium scindens and Secondary Bile Acids Inhibit the Growth of Clostridium difficile

Dysfunctional Families: Clostridium scindens and Secondary Bile Acids Inhibit the Growth of Clostridium difficile

Update on intestinal microbiota in Crohn's disease 2017: Mechanisms, clinical application, adverse reactions, and outlook

Control of Clostridium difficile Infection by Defined Microbial Communities

Contact Info

Product

Resources

About